Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

    Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

    FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

    Start listeningView podcast show

    Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

    FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

    ratings:
    Length:
    16 minutes
    Released:
    Jun 25, 2021
    Format:
    Podcast episode

    Description

    Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version. 
    Released:
    Jun 25, 2021
    Format:
    Podcast episode

    Titles in the series (94)

    Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.